Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a solid tumour cancer that has been confirmed by laboratory testing of tissue or cell samples, and whose cancer has come back or stopped responding to all standard treatments available to them locally.
- People whose blood and organ tests (such as kidney, liver, and blood cell counts) show the body is functioning well enough to participate.
- People who are able to meet the trial's pregnancy prevention requirements.
- People whose cancer can be measured on scans, as assessed by the trial site using standard measurement guidelines.
- People who are generally well enough to carry out light activity and care for themselves — rated 0 or 1 on a standard scale doctors use to measure a patient's overall health and ability to do daily activities.
Who may not be able to join:
- People who have a diagnosis of a condition that weakens the immune system.
- People who have had a second, separate cancer in the past, unless treatment for that cancer was completed with no sign of cancer returning for at least 5 years. However, people with certain skin cancers, early-stage prostate cancer, non-bladder carcinoma in situ, Stage I or in-situ melanoma who have had curative treatment may still be considered, as may people with early-stage breast cancer who completed curative treatment with no recurrence for at least 2 years.
- People who currently have active, spreading cancer in the brain or the lining around the brain and spinal cord. People who had brain metastases that have already been treated may still be considered, provided scans show the cancer has been stable for at least 2 weeks, the person is clinically stable, and no steroid medication has been needed for at least 14 days before the first dose of the trial treatment.
- People who received cancer treatment — including experimental treatments — within 21 days (or within 5 half-lives of the drug, whichever is shorter) before the first dose of the trial treatment, or who have not recovered from significant side effects of previous treatments (confirm with trial site for specific exceptions around nerve-related side effects or hormone-related side effects).
- People who have previously received a stem cell transplant (using their own or a donor's cells) or a solid organ transplant.
- People who have previously been treated with a therapy that targets a protein called CD24.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 434-249-2349
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b); Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b); Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b); Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerabil...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.